Internal and Emergency Medicine

, Volume 3, Issue 1, pp 53–56

Rimonabant for overweight and “metabolic syndrome”: the attempt to supersize disease and risk by pharmaceutical marketing

  • Rita Banzi
  • Lorenzo Moja
  • Ivan Moschetti
  • Alessandro Liberati
  • Gian Franco Gensini
  • Roberto Gusinu
  • Andrea A. Conti
CE - Cochrane's Corner


  1. 1.
    Curioni C, Andre C (2006) Rimonabant for overweight or obesity. Cochrane Database Syst Rev, CD006162Google Scholar
  2. 2.
    Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389–1397PubMedCrossRefGoogle Scholar
  3. 3.
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761–775PubMedCrossRefGoogle Scholar
  4. 4.
    Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 368:1660–1672PubMedCrossRefGoogle Scholar
  5. 5.
    Despres JP, Golay A, Sjostrom L (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121–2134PubMedCrossRefGoogle Scholar
  6. 6.
    Bero L, Oostvogel F, Bacchetti P, Lee K (2007) Factors associated with findings of published trials of drug–drug comparisons: why some statins appear more efficacious than others. PLoS Med 4:e184PubMedCrossRefGoogle Scholar
  7. 7.
    Djulbegovic B et al (2000) The uncertainty principle and industry-sponsored research. Lancet 356:635–638PubMedCrossRefGoogle Scholar
  8. 8.
    Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B (2003) Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171–1173PubMedCrossRefGoogle Scholar
  9. 9.
    NHI Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults.
  10. 10.
    EMEA (2006) Guideline on clinical investigation of medicinal product used in weight control.
  11. 11.
    Rucker D, Padwal R, Li SK, Curioni C, Lau DC (2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335:1194–1199PubMedCrossRefGoogle Scholar
  12. 12.
    EMEA European Public Assessment Report (EPAR). Last accessed Jan 2007
  13. 13.
  14. 14.
    Reaven GM, Chen YD (1988) Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev 4:639–652PubMedCrossRefGoogle Scholar
  15. 15.
    Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415–1428PubMedCrossRefGoogle Scholar
  16. 16.
    Gale EA (2005) The myth of the metabolic syndrome. Diabetologia 48:1679–1683PubMedCrossRefGoogle Scholar
  17. 17.
    Heath I (2006) Combating disease mongering: daunting but nonetheless essential. PLoS Med 3:e146PubMedCrossRefGoogle Scholar
  18. 18.
    Moynihan R, Henry D (2006) The fight against disease mongering: generating knowledge for action. PLoS Med 3:e191PubMedCrossRefGoogle Scholar
  19. 19.
    Mintzes B (2006) Disease mongering in drug promotion: do governments have a regulatory role? PLoS Med 3:e198PubMedCrossRefGoogle Scholar
  20. 20.
    Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415–28PubMedCrossRefGoogle Scholar
  21. 21.
    Zimmet PZ, Alberti G (2005) Medscape diabetes & endocrinology. 7(2). Available at Accessed on January 31, 2008
  22. 22.
    Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomized trials. Lancet 370:1706–1713PubMedCrossRefGoogle Scholar
  23. 23.
    Moynihan R, Heath I, Henry D (2002) Selling sickness: the pharmaceutical industry and disease mongering. BMJ 324:886–891PubMedCrossRefGoogle Scholar

Copyright information

© SIMI 2008

Authors and Affiliations

  • Rita Banzi
    • 1
  • Lorenzo Moja
    • 1
  • Ivan Moschetti
    • 1
  • Alessandro Liberati
    • 1
  • Gian Franco Gensini
    • 2
  • Roberto Gusinu
    • 3
  • Andrea A. Conti
    • 4
  1. 1.Italian Cochrane CentreMario Negri Institute for Pharmacological ResearchMilanItaly
  2. 2.Department of Critical Care Medicine and SurgeryUniversity of Florence and Azienda Ospedaliero-Universitaria CareggiFlorenceItaly
  3. 3.DAI Cardiologico e dei Vasi, Azienda Ospedaliero-Universitaria CareggiFlorenceItaly
  4. 4.Department of Critical Care Medicine and SurgeryUniversity of Florence and Don Carlo Gnocchi Foundation IRCCSFlorenceItaly

Personalised recommendations